Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage

Evangelos J Giamarellos-Bourboulis, Emmanouel Pyleris, Charalambos Barbatzas, Aikaterini Pistiki, Mark Pimentel, Evangelos J Giamarellos-Bourboulis, Emmanouel Pyleris, Charalambos Barbatzas, Aikaterini Pistiki, Mark Pimentel

Abstract

Background: Current knowledge suggests that small intestinal overgrowth participates in the pathogenesis of irritable bowel syndrome. It is questionable if this association is modulated by intake of proton pump inhibitors (PPIs).

Methods: In a prospective study, quantitative cultures of duodenal aspirates were performed for aerobic species in 897 consecutive patients undergoing upper GI tract endoscopy. SIBO was defined as equal to or more than 10(3) cfu/ml. The effect of PPI intake on the relationship between SIBO and IBS was the primary endpoint.

Results: Analysis among patients without any history of PPI intake (n = 713) showed that odds ratio (OR) for IBS in the event of SIBO was 5.63 (3.73-8.51, p < 0.0001); this was 4.16 (1.91-9.06) when analysis was done among patients with history of PPI intake (n = 184, p: 0.498 between patients without and with PPI intake). Multiple logistic regression analysis found that factors independently associated with SIBO were age above or equal to 60 years (OR: 2.36), body mass index more than or equal to 22 kg/m(2) (OR: 0.60), presence of IBS (OR: 6.29), type 2 diabetes mellitus (OR: 1.59) and gastritis (OR: 0.47).

Conclusions: The association between IBS and SIBO was completely independent from PPI intake. Although gastritis was protective against SIBO, results show that PPI intake cannot prime SIBO.

Keywords: Irritable bowel syndrome; Proton pump inhibitors; Small intestinal overgrowth.

Figures

Fig. 1
Fig. 1
Study flow chart. Abbreviations: GI; gastrointestinal; SIBO: syndrome of intestinal bacterial overgrowth
Fig. 2
Fig. 2
Lack of association between bacterial growth in duodenal aspirates and history of PPI intake a Bacterial growth in patients without history of PPI intake [PPIs(-)] and patients with history of PPI intake [PPIs(+)]; b Bacterial growth in patients with IBS predominant diarrhea [IBS-D(+)] and the rest of patients [IBS-D(-)] in relation to the time of PPI intake. P values show differences of the indicated comparisons

References

    1. Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:1157–1160. doi: 10.1111/j.1365-2036.2005.02690.x.
    1. Nucera G, Gabrielli M, Lupascu A, Lauritano EC, Santoliquido A, Cremonini F, Cammarota G, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;2:1391–1395. doi: 10.1111/j.1365-2036.2005.02493.x.
    1. Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55:2241–2249. doi: 10.1007/s10620-010-1276-4.
    1. Yu D, Cheeseman F, Vanner S. Combined oro-faecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-faecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60:334–340. doi: 10.1136/gut.2009.205476.
    1. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321–1329. doi: 10.1007/s10620-012-2033-7.
    1. Choung RS, Ruff KC, Maljotra A, Herrick L, Locke GR, 3rd, Harmsen WS, Zinsmeister AR, Talley NJ, Saito YA. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33:1059–1067. doi: 10.1111/j.1365-2036.2011.04625.x.
    1. Camillieri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012;367:1626–1635. doi: 10.1056/NEJMra1207068.
    1. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:483–490. doi: 10.1016/j.cgh.2012.12.011.
    1. Lee HR, Pimentel M. Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 2006;8:305. doi: 10.1007/s11894-006-0051-3.
    1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(Suppl 2):1143–1147.
    1. Jacobs C, Coss Adame E, Attaluri A, Valsetin J, Rao SSC. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fundal overgrowth. Aliment Pharmacol Ther. 2013;37:1103–1111. doi: 10.1111/apt.12304.
    1. Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, Romano M, Nardone G. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest. 2011;41:380–386. doi: 10.1111/j.1365-2362.2010.02419.x.
    1. Shah SC, Day LW, Somsouk M, Sewell JJ. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38:925–934. doi: 10.1111/apt.12479.
    1. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–33. doi: 10.1056/NEJMoa1004409.
    1. Pistiki A, Galani I, Pyleris E, Barbatzas C, Pimentel M, Giamarellos-Bourboulis EJ. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents. 2014;43:236–241. doi: 10.1016/j.ijantimicag.2013.12.008.
    1. Jiang ZD, Ke S, Palazzini E, Riopel L, DuPont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44:2205–2206. doi: 10.1128/AAC.44.8.2205-2206.2000.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere